@article{0b640c6a717c44baa2c70af1b69a2833,
title = "Prior histories of posttraumatic stress disorder and major depression and their onset and course in the three months after a motor vehicle collision in the AURORA study",
abstract = "Background: A better understanding of the extent to which prior occurrences of posttraumatic stress disorder (PTSD) and major depressive episode (MDE) predict psychopathological reactions to subsequent traumas might be useful in targeting posttraumatic preventive interventions. Methods: Data come from 1306 patients presenting to 29 U.S. emergency departments (EDs) after a motor vehicle collision (MVC) in the advancing understanding of recovery after trauma study. Patients completed self-reports in the ED and 2-weeks, 8-weeks, and 3-months post-MVC. Associations of pre-MVC probable PTSD and probable MDE histories with subsequent 3-months post-MVC probable PTSD and probable MDE were examined along with mediation through intervening peritraumatic, 2-, and 8-week disorders. Results: 27.6% of patients had 3-month post-MVC probable PTSD and/or MDE. Pre-MVC lifetime histories of these disorders were not only significant (relative risk = 2.6–7.4) but were dominant (63.1% population attributable risk proportion [PARP]) predictors of this 3-month outcome, with 46.6% prevalence of the outcome among patients with pre-MVC disorder histories versus 9.9% among those without such histories. The associations of pre-MVC lifetime disorders with the 3-month outcome were mediated largely by 2- and 8-week probable PTSD and MDE (PARP decreasing to 22.8% with controls for these intervening disorders). Decomposition showed that pre-MVC lifetime histories predicted both onset and persistence of these intervening disorders as well as the higher conditional prevalence of the 3-month outcome in the presence of these intervening disorders. Conclusions: Assessments of pre-MVC PTSD and MDE histories and follow-ups at 2 and 8 weeks could help target early interventions for psychopathological reactions to MVCs.",
author = "Jutta Joormann and Ziobrowski, {Hannah N.} and King, {Andrew J.} and Gildea, {Sarah M.} and Sue Lee and Sampson, {Nancy A.} and House, {Stacey L.} and Beaudoin, {Francesca L.} and Xinming An and Stevens, {Jennifer S.} and Donglin Zeng and Neylan, {Thomas C.} and Clifford, {Gari D.} and Linnstaedt, {Sarah D.} and Germine, {Laura T.} and Bollen, {Kenneth A.} and Rauch, {Scott L.} and Haran, {John P.} and Storrow, {Alan B.} and Musey, {Paul I.} and Hendry, {Phyllis L.} and Sophia Sheikh and Jones, {Christopher W.} and Punches, {Brittany E.} and McGrath, {Meghan E.} and Hudak, {Lauren A.} and Pascual, {Jose L.} and Seamon, {Mark J.} and Chang, {Anna M.} and Claire Pearson and Peak, {David A.} and Domeier, {Robert M.} and Rathlev, {Niels K.} and O'Neil, {Brian J.} and Sanchez, {Leon D.} and Bruce, {Steven E.} and Miller, {Mark W.} and Pietrzak, {Robert H.} and Barch, {Deanna M.} and Pizzagalli, {Diego A.} and Harte, {Steven E.} and Elliott, {James M.} and Koenen, {Karestan C.} and McLean, {Samuel A.} and Kessler, {Ronald C.}",
note = "Funding Information: AURORA is supported by NIMH U01MH110925, the U.S. Army Medical Research and Materiel Command, The One Mind Foundation, and The Mayday Fund. Verily Life Sciences and Mindstrong Health provide some of the hardware and software used to perform study assessments. Funding Information: Dr. Jutta Joorman has served as a consultant for Janssen Pharmaceuticals. In the last 3 years, Dr. Gari D. Clifford has received research funding from the National Science Foundation, the National Institute of Health, and LifeBell AI; he has received unrestricted donations from AliveCor, Amazon Research, the Center for Discovery, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, the Gates Foundation, Google, One Mind Foundation, and Samsung Research; he has a financial interest in AliveCor, and has received unrestricted funding from the company; he is the chief technology officer of MindChild Medical and chief security officer of LifeBell AI, and has ownership in both companies. In the past 3 years, Dr. Laura T. Germine has served on the Scientific Advisory Board of Sage Bionetworks, for which she received a small honorarium. Dr. Scott L. Rauch has a paid role as secretary of Society of Biological Psychiatry; he has received royalties from Oxford University Press and from American Psychiatric Publishing Inc.; has paid board service from Community Psychiatry, including equity outside the submitted work; and he has served as the board of director for Anxiety and Depression Association of America, and National Network of Depression Centers. Dr. Christopher W. Jones has been an investigator on studies funded by Hologic Inc., Janssen, AstraZeneca, and Vapotherm. Over the past 3 years, Dr. Diego A. Pizzagalli has received consulting fees from BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; he has one honorarium from Alkermes; he has received research funding from Millennium Pharmaceuticals; and he has received stock options from BlackThorn Therapeutics. Dr. Steven E. Harte has received personal fees from the National Institute of Health/the University of North Carolina at Chapel Hill, Aptinyx, Heron Therapeutics, Memorial Sloan Cancer Center, and Eli Lilly; he has received grants from Aptinyx and Arbor Medical Innovations; and he reports membership to Arbor Medical Innovations. Dr. James M. Elliot has received grants from the National Institutes of Health. In the past 3 years, Dr. Ronald C. Kessler has served as a consultant for Datastat, Inc., Holmusk, RallyPoint Networks, Inc., and Sage Therapeutics and he has stock options in Mirah, PYM, and Roga Sciences. All other authors declare that there are no conflicts of interest. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",
year = "2022",
month = jan,
doi = "10.1002/da.23223",
language = "English",
volume = "39",
pages = "56--70",
journal = "Depression and Anxiety",
issn = "1091-4269",
number = "1",
}